Cardiff Oncology Inc (CRDF) - News Archive

At the recent American Society of Clinical Oncology (ASCO) 2025 meeting, Cardiff Oncology presented promising results from an investigator-initiated Phase 1b clinical trial evaluating the combination of onvansertib and...

The landscape of drug development for metastatic colorectal cancer (mCRC) is ever-evolving, with a focus on targeted therapies that can improve patient outcomes. Cardiff Oncology Inc. recently announced positive initial...

In a recent announcement, Cardiff Oncology unveiled the results for the fourth quarter and full year of 2023, along with an exciting business update. The company reported substantial progress towards their new lead prog...